S100A2 Antibody
(Synonyms: CAN19, S100L)S100A2 Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100A2.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P
-
Reactivity :
Human
-
Formulation:
Supplied in PBS, Glycerol and BSA
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:50-1:100 |
Product Details
S100A2 Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100A2.
-
Host Rabbit
-
Clonality Polyclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 13 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 11 kDa
Fusion protein of human S100A2
Endogenous
Protein A
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, Glycerol and BSA
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
S100A2 is an EF-hand Ca2+-binding S100 protein that localizes in keratinocyte cytoplasm and nucleus, forms dimers, and undergoes oxidative cross-linking[1]. Mechanistically, S100A2 interacts with p53 in a Ca2+-dependent manner and increases p53 transcriptional activity, linking calcium signaling to cell-cycle control[2]. BRCA1 and p63 also coregulate S100A2, connecting this isoform to mutant p53 stability in breast cancer models[3]. In epithelial cancer models, S100A2 restrains squamous carcinoma cell motility through actin microfilament dynamics, supporting a tumor-suppressive migration phenotype[4]. In pancreatic cancer, however, S100A2 promotes EMT and metastasis through TGF-β/SMAD4 signaling, showing context-dependent disease relevance[5]. Compared with related S100 isoforms such as S100A4, S100A2 shows distinct expression and target-gene patterns in lung adenocarcinoma, making isoform-specific analysis essential[6]. For experimental applications, 3,5-bis (trifluoromethyl) benzene sulfonamides and 1,2,3-triazoles have been designed as small-molecule leads targeting the S100A2-p53 interaction in pancreatic cancer cell studies[7][8].
-
Expression
Tissue_specificity:A subset of epithelial cells including normal human mammary epithelial cells and keratinocytes
Induction:By growth factors in early G1 phase and probably by cell-cycle regulation in S phase. DNA methylation probably plays a direct negative role in suppressing S100L gene expression in tumor cells -
Subunit
Homodimer. Interacts with FKBP4. Interacts with PPP5C (via TPR repeats); the interaction is calcium-dependent and modulates PPP5C activity. Interacts with TPPP; this interaction inhibits TPPP dimerization (PubMed:33831707)
-
SwissProt ID
-
Synonyms
CAN19, S100L
-
Research Field
Cell biology
Documentation
[1]. Deshpande R, et al. Biochemical characterization of S100A2 in human keratinocytes: subcellular localization, dimerization, and oxidative cross-linking. J Invest Dermatol. 2000 Sep;115(3):477-85. [Content Brief]
[2]. Mueller A, et al. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem. 2005 Aug 12;280(32):29186-93. [Content Brief]
[3]. Buckley NE, et al. S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability. Cell Death Dis. 2014 Feb 20;5(2):e1070. [Content Brief]
[4]. Nagy N, et al. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest. 2001 Apr;81(4):599-612. [Content Brief]
[5]. Chen Q, et al. S100A2 induces epithelial-mesenchymal transition and metastasis in pancreatic cancer by coordinating transforming growth factor β signaling in SMAD4-dependent manner. Cell Death Discov. 2023 Sep 27;9(1):356. [Content Brief]
[6]. Matsubara D, et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci. 2005 Dec;96(12):844-57. [Content Brief]
[7]. Sun J, et al. Targeting the S100A2-p53 Interaction with a Series of 3,5-Bis(trifluoromethyl)benzene Sulfonamides: Synthesis and Cytotoxicity. ChemMedChem. 2021 Sep 16;16(18):2851-2863. [Content Brief]
[8]. Sun J, et al. Cytotoxic 1,2,3-Triazoles as Potential Leads Targeting the S100A2-p53 Complex: Synthesis and Cytotoxicity. ChemMedChem. 2021 Sep 16;16(18):2864-2881. [Content Brief]
Powered by Bioz
